New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and …
CA Hughes, L Robinson, A Tseng… - Expert opinion on …, 2009 - Taylor & Francis
Background: The introduction and approval of new antiretroviral agents in the US and
Canada bring new opportunities and new challenges. Arguably, for the first time ever …
Canada bring new opportunities and new challenges. Arguably, for the first time ever …
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients
M Youle - Journal of antimicrobial chemotherapy, 2007 - academic.oup.com
Antiretroviral drug combinations that include two nucleoside reverse transcriptase inhibitors
and a protease inhibitor (PI) can suppress HIV replication to undetectable levels, improving …
and a protease inhibitor (PI) can suppress HIV replication to undetectable levels, improving …
Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized …
SL Walmsley, C Katlama, A Lazzarin… - JAIDS Journal of …, 2008 - journals.lww.com
Background: Given the limited treatment options for patients with high-level resistance,
antiretroviral (ARV) regimens based on concomitant use of 2 ritonavir (RTV)-boosted …
antiretroviral (ARV) regimens based on concomitant use of 2 ritonavir (RTV)-boosted …
Tipranavir: a protease inhibitor for HIV salvage therapy
BJ Dong, JM Cocohoba - Annals of Pharmacotherapy, 2006 - journals.sagepub.com
Objective: TO review the efficacy, safety, pharmacology, virology, pharmacokinetics, and
resistance of the nonpeptidic protease inhibitor (PI) tipranavir. Data Sources and Study …
resistance of the nonpeptidic protease inhibitor (PI) tipranavir. Data Sources and Study …